Log in or register to see all Alerts
New HTA Decisions in Germany
March 2021
Drug name
TALTZ® (ixekizumab)
Company
Lilly Deutschland GmbH
Decision date
26/01/2021
Therapeutic area
Musculoskeletal conditions
Therapeutic sub area
Arthritis
G-BA decision date
21/01/2021
Orphan Drug?
No
Decision
No additional benefit
Indication
Adult patients with active ankylosing spondylitis who did not respond adequately to the conventional therapy or who have an intolerance to this. Main comparator: TNF-α inhibitor (etanercept or adalimumab or infliximab or golimumab or certolizumab pegol) or an IL17 inhibitor (secukinumab).
Decision
No additional benefit
Indication
Adult patients with active ankylosing spondylitis who did not respond adequately to previous therapy with bDMARD or who have an intolerance to this. Main comparator: Change to another bDMARD: TNF-α inhibitor (adalimumab or certolizumab pegol or etanercept or golimumab or infliximab) or an IL17 inhibitor (secukinumab).
Decision
No additional benefit
Indication
Adult patients with active axial spondyloarthritis without X-ray evidence of ankylosing spondylitis, but with objective signs of inflammation due to increased CRP and / or MRIs who do not respond adequately to conventional therapy or who have an intolerance to this.
Decision Detail
Main driver of decision: There were no appropriate studies presented which allowed direct comparison of the drug and comparator.
Summary
IQWiG concluded that there was no additional benefit of ixekizumab in any indication.